Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OCUP NYSE:OSTX NASDAQ:VIRI NASDAQ:WHWK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOCUPOcuphire Pharma$1.26$1.07▼$3.40$30.33M0.2171,840 shs676,700 shsOSTXOS Therapies$2.26-9.6%$1.86$1.12▼$7.00$72.08MN/A742,497 shs834,233 shsVIRIVirios Therapeutics$4.65-6.8%$4.85$0.13▼$1.04$89.55M1.581.05 million shs27,858 shsWHWKWhitehawk Therapeutics$1.77-2.2%$1.83$1.39▼$3.81$83.42M0.55150,894 shs145,185 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOCUPOcuphire Pharma0.00%0.00%0.00%0.00%-4.10%OSTXOS Therapies+7.30%+14.16%+38.89%+58.23%-38.12%VIRIVirios Therapeutics-1.38%+3.74%+4.61%-12.46%+2,309.46%WHWKWhitehawk Therapeutics0.00%+9.70%0.00%+180,999,900.00%+180,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOCUPOcuphire PharmaN/AN/AN/AN/AN/AN/AN/AN/AOSTXOS Therapies2.2037 of 5 stars3.60.00.00.02.40.80.6VIRIVirios TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AWHWKWhitehawk TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOCUPOcuphire Pharma 3.00Buy$10.00∞ UpsideOSTXOS Therapies 3.25Buy$18.00696.46% UpsideVIRIVirios Therapeutics 2.00Hold$5.007.53% UpsideWHWKWhitehawk Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest OCUP, VIRI, WHWK, and OSTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.008/20/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.008/11/2025WHWKWhitehawk TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell8/7/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.007/14/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/30/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/24/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/9/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOCUPOcuphire Pharma$16.45M0.00N/AN/A$2.20 per share0.00OSTXOS TherapiesN/AN/AN/AN/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/A$0.20 per shareN/AWHWKWhitehawk Therapeutics$25.98M3.21N/AN/A$3.65 per share0.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOCUPOcuphire Pharma-$9.99M-$0.49N/AN/AN/A-85.75%-30.19%-27.55%N/AOSTXOS Therapies-$7.79M-$0.79N/AN/AN/AN/AN/A-569.57%N/AVIRIVirios Therapeutics-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%N/AWHWKWhitehawk Therapeutics-$63.69M-$0.06N/A∞N/A99.42%-75.99%-68.57%N/ALatest OCUP, VIRI, WHWK, and OSTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025WHWKWhitehawk Therapeutics$0.49-$0.76-$1.25-$0.76$100.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOCUPOcuphire PharmaN/AN/AN/AN/AN/AOSTXOS TherapiesN/AN/AN/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/AN/AWHWKWhitehawk TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOCUPOcuphire PharmaN/A10.6810.68OSTXOS TherapiesN/A0.760.76VIRIVirios TherapeuticsN/A7.277.27WHWKWhitehawk TherapeuticsN/A20.4120.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOCUPOcuphire Pharma14.97%OSTXOS TherapiesN/AVIRIVirios Therapeutics9.05%WHWKWhitehawk Therapeutics52.08%Insider OwnershipCompanyInsider OwnershipOCUPOcuphire Pharma8.70%OSTXOS Therapies13.80%VIRIVirios Therapeutics12.20%WHWKWhitehawk Therapeutics49.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOCUPOcuphire Pharma1425.92 million24.47 millionOptionableOSTXOS TherapiesN/A31.89 millionN/AN/AVIRIVirios Therapeutics519.26 million16.91 millionOptionableWHWKWhitehawk Therapeutics4047.13 million23.61 millionN/AOCUP, VIRI, WHWK, and OSTX HeadlinesRecent News About These CompaniesWhitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Misses Expectations By $1.25 EPSAugust 10, 2025 | marketbeat.comWhitehawk Therapeutics (NASDAQ:WHWK) Downgraded to "Strong Sell" Rating by Wall Street ZenAugust 10, 2025 | marketbeat.comWhitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent HighlightsAugust 7, 2025 | prnewswire.comWhitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 22, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCUP, VIRI, WHWK, and OSTX Company DescriptionsOcuphire Pharma NASDAQ:OCUPOcuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.OS Therapies NYSE:OSTX$2.26 -0.24 (-9.60%) Closing price 04:00 PM EasternExtended Trading$2.28 +0.03 (+1.11%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.Virios Therapeutics NASDAQ:VIRI$4.65 -0.34 (-6.81%) As of 08/27/2025Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.Whitehawk Therapeutics NASDAQ:WHWK$1.77 -0.04 (-2.21%) As of 04:00 PM EasternAadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike at a Crossroads: AI Halo vs. Risks NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality Okta: Market Comes to a Boil, Explosive Upside Is Possible MongoDB Roars Back to Life: It’s Not Too Late to Buy More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access